Self-admininistration Moxibustion for Dyslipidemia in Diabetic Patients

Self-admininistration Moxibustion for Dyslipidemia in Diabetic Patients: A double-blind randomized control study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210427004

Enrollment

Registered

2021-04-27

Start date

2021-03-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients aged between 35-60 year old with serum LDL-cholesterol between 100-189 mg/dL Self-moxibustion Diabetic patient Dyslipidemia

Interventions

self-moxibustion at active acupoint (ST 40)30 min twice a week for 8 weeks,self-moxibustion at placebo acupoint (ST 37)30 min twice a week for 8 weeks

Active Comparator Device,Placebo Comparator Device

self-moxibustion at acupoint ST40,self-moxibustion at acupoint ST37

Eligibility

Sex/Gender

All

Age

35 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Diabetic patients aged between 35-60 years old 2. Serum LDL-cholesterol between 100-189 mg/dL 3. Non smoker, no alcohol drinking 4. No following medical conditions: uncontrolled hypertension, coronary heart diseases, stroke.

Exclusion criteria

Exclusion criteria: 1. History of epilepsy 2. Recent lesions on selected acupoint 3. Pregnancy 4. Diabetic peripheral neuropathy

Design outcomes

Primary

Measure	Time frame
LDL-Cholesterol 8 weeks after the end of experiment enzymatic test by spectrophotometer	—

Secondary

Measure	Time frame
FBS, HDL, Total cholesterol, Triglyceride 8 weeks after the end of study enzymatic test by spectrophotometer	—

Countries

Thailand

Contacts

Public ContactTawat Buranatawonsom

Dhurakij Pundit University

625159100039@dpu.ac.th029547300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026